NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

NCT01663727

CompletedPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Metastatic Breast Cancer

Interventions: Bevacizumab [Avastin], Paclitaxel, Placebo

Countries: United States, Argentina, Belgium, Brazil, Bulgaria, Chile, Germany, Italy

This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or placebo (10 mg/kg) will be administered by IV infusion on Days 1 and 15 of each 28-day cycle. Patients will be treated until disease progression, unacceptable toxicity or death from any cause occurs.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.
* ECOG performance status of 0 or 1
* For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception
* For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization

Exclusion Criteria:

Disease-Specific Exclusions:

* HER2-positive status
* Prior chemotherapy for locally recurrent or metastatic disease
* Prior hormonal therapy \< 2 weeks prior to randomization
* Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization
* Investigational therapy within 28 days of randomization

General Medical Exclusions:

* Life expectancy of \< 12 weeks
* Inadequate organ function
* Uncontrolled serious medical or psychiatric illness
* Active infection requiring intravenous (IV) antibiotics at screening
* Pregnancy or lactation
* History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death

Locations (178)

Birmingham, Alabama, United States
Tucson, Arizona, United States
Corona, California, United States
Glendora, California, United States
La Verne, California, United States
Long Beach, California, United States
Palm Springs, California, United States
Pomona, California, United States
Rancho Cucamonga, California, United States
West Covina, California, United States
Washington D.C., District of Columbia, United States
Deerfield Beach, Florida, United States
Fort Myers, Florida, United States
Plantation, Florida, United States
Port Saint Lucie, Florida, United States
Athens, Georgia, United States
Atlanta, Georgia, United States
Honolulu, Hawaii, United States
Indianapolis, Indiana, United States
Baltimore, Maryland, United States
Columbia, Maryland, United States
Burlington, Massachusetts, United States
New Albany, Mississippi, United States
Columbia, Missouri, United States
St Louis, Missouri, United States
Hackensack, New Jersey, United States
Middletown, Ohio, United States
Sylvania, Ohio, United States
Toledo, Ohio, United States
Leesburg, Pennsylvania, United States
+ 148 more on CT.gov